Innovator U.S. Equity Ultra Buffer ETF - August (BATS: UAUG)

Latest news for Innovator U.S. Equity Ultra Buffer ETF - August (BATS:UAUG)

The fund invests at least 80% of its net assets in FLexible EXchange Options (FLEX Options) that reference the S&P 500 Price Return Index (S&P 500 Price Index). FLEX Options are exchange-traded options contracts with uniquely customizable terms. It is non-diversified.

Innovator US Equity Ultra Buffer ETF - August

Innovator U.S. Equity Ultra Buffer ETF - August

WIIM

QBTS

D-Wave Quantam shares are trading higher after AWS announced Quantum Embark program.

TN-401 AAV9-based Gene Therapy Designed to Deliver Fully Functional PKP2 Gene with the Aim of Increasing Protein Levels to Address Underlying Disease
RIDGE-1 Currently Enrolling at Six Centers; Observational Natural History and Seroprevalence Study of PKP2-associated ARVC Adults Continues Enrollment at 20 Clinical Sites in the U.S., UK and Europe
Initial Clinical Data for RIDGE-1 Anticipated in 2025

Biotech

News

General

TNYA

Tenaya Therapeutics Doses First Patient In RIDGE-1 Phase 1b Clinical Trial Of TN-401 For Treatment Of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy

Top cryptocurrencies like Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>), Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>), Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>), and XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>) are seeing declining bullish sentiment despite rising <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41629253/satoshi-nakamoto-could-soon-be-surpassed-by-blackrock-grayscale-as-top-bitcoin-holder">cost bases for holders</a>.
What Happened: Santiment data shows the crypto market sentiment, which had been bullish following a prolonged rally since September, cooling down, particularly for top-cap assets like Bitcoin and Ethereum.
Despite Bitcoin nearly hitting the $100,000 milestone, its recent price stagnation and social sentiment dip suggest a rise in pessimism among traders. 
This shift occurred notably after the <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41951961/bitcoin-to-100k-benzinga-readers-predict-if-btc-can-hit-new-milestone-before-end-of-2024">U.S. presidential election</a>, where euphoria peaked but faded as Bitcoin ranged around $99,800.
While Bitcoin, Ethereum and Solana show modest gains, their social sentiment has dipped. XRP, despite breaking $1.60 for the first time in years, is also facing skepticism.
Smaller altcoins like Stellar (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xlm/usd">XLM</a>), Polkadot (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/dot/usd">DOT</a>) and Celestia (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">TIA</a>) are gaining attention with significant market cap and social volume increases, drawing focus away from top caps.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42160774/microstrategy-is-the-bitcoin-magnet-says-bernstein-but-not-everybodys-sold-nothing-is-free-in-finance-says-one-analyst">MicroStrategy Is The &#8216;Bitcoin Magnet,&#8217; Says Bernstein, But Not Everybody&#8217;s Sold: &#8216;Nothing Is Free In Finance,&#8217; Says One Analyst</a>
Why It Matters: IntoTheBlock <a href="https://x.com/intotheblock/status/1860974070696685992">data</a> shows that the battle for $100,000 Bitcoin continues as 458,000 addresses accumulated a significant 344,000 BTC. 
This could be a strong foundation to fuel beyond $100,000. 60,000 addresses <a href="https://x.com/intotheblock/status/1860974070696685992">acquired</a> 22,740 BTC above the current price.
Low sentiment often signals potential upside, while euphoric spikes tend to precede corrections. The crypto market's current phase reflects a temporary shift in focus rather than a long-term bearish turn.
What's Next: The Thanksgiving week slump might be setting the stage for a broader market correction, which could rejuvenate Bitcoin and other top assets. 
As Santiment <a href="https://x.com/santimentfeed/status/1860978080216498523">notes</a>, when traders overlook Bitcoin for smaller pumping altcoins, it often marks the perfect setup for BTC to make a strong comeback.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42155010/bitcoins-bull-run-betting-on-a-125k-finish-to-2024">Bitcoin&#8217;s Bull Run: Betting On A $125K Finish To 2024</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$DOT

$ETH

$SOL

$TIA

$XLM

$XRP

Why Bitcoin's Rally Is Stalling Below $100,000

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the information technology sector.
<h3 class="wp-block-heading">Xerox Holdings Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRX#NASDAQ">XRX</a>)</h3>
<ul>
<li>Dividend Yield: 11.06%</li>
<li>JP Morgan analyst Samik Chatterjee maintained an Underweight rating and lowered the price target from $11 to $8 on Oct. 30. This analyst has an accuracy rate of 71%.</li>
<li>Loop Capital analyst Ananda Baruah maintained a Hold rating and cut the price target from $14 to $11 on Aug. 14. This analyst has an accuracy rate of 75%.</li>
<li>Recent News: On Oct. 29, Xerox reported worse-than-expected third-quarter financial results and cut annual outlook.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112524&amp;t=be2bearmibe3na1">latest XRX news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112524&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="912" height="856" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25045306/image-264.png" alt="" class="wp-image-662968" style="width:719px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25045306/image-264.png 912w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25045306/image-264-300x282.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25045306/image-264-768x721.png 768w" sizes="(max-width: 912px) 100vw, 912px" /></a></figure>
<h3 class="wp-block-heading">Skyworks Solutions, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWKS#NASDAQ">SWKS</a>)</h3>
<ul>
<li>Dividend Yield: 3.28%</li>
<li>Citigroup analyst Atif Malik maintained a Sell rating and cut the price target from $83 to $72 on Nov. 13. This analyst has an accuracy rate of 82%.</li>
<li>Mizuho analyst Vijay Rakesh maintained an Outperform rating and cut the price target from $127 to $105 on Nov. 13. This analyst has an accuracy rate of 75%.</li>
<li>Recent News: On Nov. 12, the company reported adjusted EPS of $1.55, which beat the analyst consensus estimate of $1.52. Quarterly sales of $1.025 million were in line with the analyst consensus estimate.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112524&amp;t=be2bearmibe3na1">latest SWKS news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112524&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="783" height="791" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25045415/image-265.png" alt="" class="wp-image-662970" style="width:648px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25045415/image-265.png 783w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25045415/image-265-297x300.png 297w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25045415/image-265-768x776.png 768w" sizes="(max-width: 783px) 100vw, 783px" /></a></figure>
<h3 class="wp-block-heading">Methode Electronics, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MEI#NYSE">MEI</a>)</h3>
<ul>
<li>Dividend Yield: 5.35%</li>
<li>Jefferies analyst Saree Boroditsky initiated coverage on the stock with a Hold rating and a price target of $12 on April 9. This analyst has an accuracy rate of 62%.</li>
<li>Sidoti &amp; Co. analyst John Franzreb downgraded the stock from Buy to Neutral on March 7. This analyst has an accuracy rate of 74%.</li>
<li>Recent News: Methode Electronics will announce second quarter results on Thursday, Dec. 5.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112524&amp;t=be2bearmibe3na1">trend in MEI stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112524&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="915" height="842" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25045456/image-266.png" alt="" class="wp-image-662971" style="width:754px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25045456/image-266.png 915w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25045456/image-266-300x276.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25045456/image-266-768x707.png 768w" sizes="(max-width: 915px) 100vw, 915px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42137942/jim-cramer-says-this-stock-is-a-bitcoin-play-and-he-prefers-to-own-bitcoin">Jim Cramer Says This Stock Is A Bitcoin Play And He Prefers To Own Bitcoin</a></li>
</ul>

Long Ideas

Price Target

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

SWKS

Wall Street's Most Accurate Analysts Give Their Take On 3 Tech Stocks Delivering High-Dividend Yields

GAIN

Gladstone Investment Acquires Pyrotek Special Effects; Gladstone Provided Equity And Senior Secured Debt To Complete Transaction

Looking into the current session, LKQ Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LKQ#NASDAQ">LKQ</a>) shares are trading at $38.76, after a 0.68% increase. Moreover, over the past month, the stock went up by 3.02%, but in the past year, decreased by 14.39%. Shareholders might be interested in knowing whether the stock is undervalued, even if the company is performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2024/1732542306_0.png" alt="Past Year Chart" />

<h3>How Does LKQ P/E Compare to Other Companies?</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
LKQ has a lower P/E than the aggregate P/E of 17.29 of the Distributors industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1732542306_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

P/E Ratio Insights for LKQ

CDZI

Cadiz And Lytton Rancheria of California Sign LOI For Lytton To Invest Up To $50M In Co.'s Groundwater Banking Project In The Mojave Desert

ELAB

Elevai Labs shares are trading lower after the company announced a 1-200 reverse stock spilt to maintain its NASDAQ listing.

Under the PPA secured by VES1, VES1 shall have a first right of refusal for in the case that the off-taker wishes to expand the solar capacity at the particular site. Based on the current assessment, VES1 shall have a first right for expansion of the solar project, totalling 50MWp installation with 60MWh energy storage in 2025, and 58MWp solar project with 50MWh energy storage in 2026. These projects will significantly enhance solar and energy storage capacity in Vietnam. The agreement also grants Founder Group exclusive rights to future rooftop solar and energy storage projects in Vietnam secured by VES1 for the next three years.

Founder Group Announces Proposed Acquisition Of Majority Stake In VES 1 Joint Stock Company; To Acquire ~80% Of Shares

ALLT

Allot Limited shares are trading higher after the company announced better-than-expected financial results.

Nuveen California Dividend Advantage Municipal Fund 2

Uxin Limited shares are trading higher after the company announced it had secured a 32,000-tonne offtake agreement with Volkswagen.

IFx-2.0, a first-in-class innate immune response agonist, entering single Phase 3 accelerated approval registration trial in first half of 2025 for first line treatment of Merkel Cell Carcinoma (MCC) under Special Protocol Assessment (SPA) agreement with U.S. Food and Drug Administration (FDA)
Entered into a non-binding letter of intent with Kineta regarding a potential transaction in which TuHURA would acquire the rights to KVA12123 expanding its pipeline with a Phase 2 ready, novel VISTA inhibiting antibody
Advancing IFx-3.0, the first systemically administered tumor-targeted mRNA innate immune response agonist for aggressive B Cell Lymphoma
Early discovery programs designing first-in-class tumor microenvironment modulating bi-specific antibody drug conjugates (ADCs) or peptide drug conjugates (PDCs) targeting Myeloid Derived Suppressor Cells (MDSCs)
Company expands leadership team with key clinical and regulatory appointments to drive strategy and operational execution

HURA

TuHURA Biosciences Outlines Development Pathway For Single Phase 3 Accelerated Approval Registration Trial

Legal

ICCM

IceCure Medical Receives Notice Of Allowance From Japan Patent Office For Invention Titled 'Cryogenic System With Multiple Submerged Pumps'

HC Wainwright &amp; Co. analyst Vernon Bernardino reiterates NRX Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRXP#NASDAQ">NRXP</a>) with a Buy and maintains $19 price target.

Reiteration

NRXP

HC Wainwright & Co. Reiterates Buy on NRX Pharmaceuticals, Maintains $19 Price Target

- Interim results indicate cognitive improvement in the active treatment group compared to placebo
- No serious adverse events or deaths reported in the trial

IGC Pharma Announces Additional Phase 2 Interim Data Highlighting IGC-AD1 For Alzheimer's Treatment

Vertical Aerospace Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVTL#NYSE">EVTL</a>) shares are trading higher premarket on Monday. The company disclosed a signed term sheet with its majority shareholder, Stephen Fitzpatrick, and primary creditor, <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b42158754/vertical-aerospace-announces-50-million-in-new-funding-as-part-of-180-million-transaction-that-wil" rel="noreferrer noopener">Mudrick Capital Management</a>.
The term sheet outlines a $50 million funding commitment from Mudrick Capital, with $25 million in upfront funding and an additional $25 million backstop, which can be reduced by third-party funding.
Stephen Fitzpatrick also has the option to invest an additional $25 million on the same terms.
This funding is expected to support the company&#8217;s Flightpath 2030 Strategy, aimed at positioning Vertical as a global leader in the eVTOL market by the decade&#8217;s end, including the ongoing development and certification of the VX4.
As part of the agreement, Vertical Aerospace&#8217;s founder, Stephen Fitzpatrick, will stay on the board to provide ongoing strategic direction as the company advances through its certification program.
To strengthen its balance sheet, the company will convert approximately&nbsp;$130 million&nbsp;of convertible notes (50%&nbsp;of the outstanding amount) into equity at&nbsp;$2.75&nbsp;per share, significantly reducing debt.
The conversion price for the remaining convertible notes is set at $3.50 per share, which supports future fundraising.
The repayment date for the remaining loan has been extended to December 2028, providing additional security during Vertical&#8217;s certification process.
Stuart Simpson, CEO of Vertical Aerospace, said, &#8220;This funding agreement underscores the strong confidence of our investors in our Flightpath 2030 Strategy and our ambition to lead the global eVTOL market.&#8221;
&#8220;By addressing our more immediate capital needs and positioning us well to secure funding for the long-term, we can focus on advancing our piloted flight test programme and bringing the VX4 to market.&#8221;
Price Action: EVTL shares are up 7.31% at $5.14 premarket at the last check Monday.
Photo via Midjourney
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/42158580" target="_blank" rel="noreferrer noopener">How Tim Cook&#8217;s Strategy To Win Over Trump Gave Apple A Competitive Edge, And Why Sundar Pichai, Mark Zuckerberg And Others Might Be Following His Playbook</a></li>
</ul>

Equities

Financing

Contracts

Small Cap

Movers

EVTL

Vertical Aerospace Soars: $50 Million Funding Boost And Debt Conversion Propel eVTOL Maker Forward

APTO

Aptose Biosciences shares are trading lower after the company announced the pricing of an $8M public offering.

Guidance

Sciencejoy Holding Sees Q4 Net Revenues RMB300-RMB330M

HC Wainwright &amp; Co. analyst Raghuram Selvaraju maintains Rockwell Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMTI#NASDAQ">RMTI</a>) with a Buy and lowers the price target from $9 to $7.

RMTI

HC Wainwright & Co. Maintains Buy on Rockwell Medical, Lowers Price Target to $7

Best Buy Co., Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBY#NYSE">BBY</a>) will release earnings results for its third quarter, before the <a href="https://www.benzinga.com/quote/BBY/earnings">opening bell on Tuesday, Nov. 26</a>.
Analysts expect the Richfield, Minnesota-based bank to report quarterly earnings at $1.29 per share, compared to $1.29 per share in the year-ago period. Best Buy projects to report revenue of $9.63 billion for the recent quarter, compared to $9.76 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On Friday, JPMorgan maintained an Overweight rating on the stock and raised its price target from $111 to $117.
With the recent buzz around Best Buy, some investors may be eyeing potential gains from the company's dividends, too. As of now, Best Buy offers an annual dividend yield of 4.20%. That&#8217;s a quarterly dividend of 94 cents per share ($3.76 a year).
So, how can investors exploit its dividend yield to pocket a regular $500 monthly?
To earn $500 per month or $6,000 annually from dividends alone, you would need an investment of approximately $142,906 or around 1,596 shares. For a more modest $100 per month or $1,200 per year, you would need $28,563 or around 319 shares.
To calculate: Divide the desired annual income ($6,000 or $1,200) by the dividend ($3.76 in this case). So, $6,000 / $3.76 = 1,596 ($500 per month), and $1,200 / $3.76 = 319 shares ($100 per month).
Note that dividend yield can change on a rolling basis, as the dividend payment and the stock price both fluctuate over time.
How that works: The dividend yield is computed by dividing the annual dividend payment by the stock&#8217;s current price.
For example, if a stock pays an annual dividend of $2 and is currently priced at $50, the dividend yield would be 4% ($2/$50). However, if the stock price increases to $60, the dividend yield drops to 3.33% ($2/$60). Conversely, if the stock price falls to $40, the dividend yield rises to 5% ($2/$40).
Similarly, changes in the dividend payment can impact the yield. If a company increases its dividend, the yield will also increase, provided the stock price stays the same. Conversely, if the dividend payment decreases, so will the yield.
BBY Price Action: Shares of Best Buy gained 3.5% to close at $89.54 on Friday.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42137942/jim-cramer-says-this-stock-is-a-bitcoin-play-and-he-prefers-to-own-bitcoin">Jim Cramer Says This Stock Is A Bitcoin Play And He Prefers To Own Bitcoin</a></li>
</ul>
Image: Shutterstock

Earnings

How To Earn $500 A Month From Best Buy Stock Ahead Of Q3 Earnings

Bird's Eye View Of Price And Risk

Rates And The Dollar May See A Massive Breakout, Weighing On Risk Assets

Growth Vs. Inflation: The Incoming Administration's Delicate Task

The National Debt: What It Means For Investors

Elections, Inflation, And The Bond Market

Weekly Commentary: The Rave

Weekly Indicators: Short-Term Forecast Very Positive, While Nowcast Hits A Soft Patch

The Federal Reserve Has Engineered A Recess Of Its Asset Hemorrhaging

Weekly Market Pulse: Don't Be A Sheep

Markets Do Cartwheels In Response To Traditional Pick For U.S. Treasury Secretary

Comments

Innovator U.S. Equity Ultra Buffer ETF - August

News

Latest news for Innovator U.S. Equity Ultra Buffer ETF - August (BATS:UAUG)

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga